Key result
Optimal antithrombotic therapy post-TAVI lacks clear evidence to balance embolic and bleeding risks.
Why the study?
There is no clear evidence on the best antithrombotic regimen before, during, and after TAVI despite recognition of stroke and bleeding risks.
This review highlights the ongoing uncertainty and discusses mechanisms regarding the optimal antithrombotic regimen for patients undergoing TAVI to balance stroke and bleeding risks.
No takes yet. Share an insight, caveat, or question.
TAVI antithrombotic regimens lack clear evidence; leaves open the need for RCTs to define optimal therapy balancing thrombosis and bleeding.
Barbanti et al. (2015) conducted a review in Transcatheter aortic valve implantation (TAVI). Antithrombotic therapy was evaluated. This review discusses the mechanisms of embolic and bleeding complications following TAVI and highlights the current lack of clear evidence regarding the optimal antithrombotic regimen.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: